Post-TKA abelacimab reduced VTE at 8 to 12 d compared with enoxaparin
- PMID: 34871049
- DOI: 10.7326/ACPJ202112210-136
Post-TKA abelacimab reduced VTE at 8 to 12 d compared with enoxaparin
Abstract
Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385:609-17. 34297496.
Comment on
-
Abelacimab for Prevention of Venous Thromboembolism.N Engl J Med. 2021 Aug 12;385(7):609-617. doi: 10.1056/NEJMoa2105872. Epub 2021 Jul 19. N Engl J Med. 2021. PMID: 34297496 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical